Search

Displaying results 1511 - 1520 of 3601 in total
  1. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    [A261120] Pozelimab is a human, monoclonal immunoglobulin G4<sup>P</sup> antibody against the terminal complement protein C5. … [A261115] The loss of CD55 can therefore induce complement hyperactivation, causing the unwanted formation of membrane-attacking complex and resulting in paroxysmal nocturnal hemoglobinuria and complement-mediated

  2. Drug

    Anacaulase

    go.drugbank.com/drugs/DB17449
    ApprovedInvestigational

    Removing eschar (a process also known as debridement) through surgical procedures can lead to significant trauma, major blood and heat loss and adjacent tissue damage.

    Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
  3. Target

    Serotonin Receptors

    go.drugbank.com/bio_entities/BE0004862
    TargetHumans

    Receptor for lasmiditan, a drug for the treatment of acute migraine (PubMed:34239069). … G protein-coupled receptor for 5-hydroxytryptamine (serotonin) (PubMed:10452531, PubMed:1565658, PubMed:1652050, PubMed:33762731).

    Polypeptides: 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 1BSynonyms: Serotonin receptor 1A, Serotonin receptor 1B
  4. Drug

    Cilgavimab

    go.drugbank.com/drugs/DB16393
    ApprovedInvestigational

    Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of blocking this interaction

  5. Drug

    Tixagevimab

    go.drugbank.com/drugs/DB16394
    ApprovedInvestigational

    Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of blocking this interaction

  6. Drug

    Salmeterol

    go.drugbank.com/drugs/DB00938
    ApprovedInvestigational

    [L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. … Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.

    Mixtures: SERETIDE 'OSP' INHALADOR 25/50 MCG, SERETIDE 'OSP' INHALADOR 25/50 MCGCategories: Adrenergic beta-2 Receptor Agonists, Cytochrome P-450 Substrates
  7. Drug

    Phenobarbital

    go.drugbank.com/drugs/DB01174
    ApprovedInvestigational

    It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.

    Mixtures: PB Hyos, Re-PB HyosCategories: P-glycoprotein inducers, P-glycoprotein substrates
  8. Drug

    GYM329

    go.drugbank.com/drugs/DB18590
    Investigational

    GYM329 is a recombinant humanized IgG1-based monoclonal antibody which binds to human latent myostatin in a pH-dependent manner

    Synonyms: recombinant humanized IgG1-based monoclonal antibody which binds to human latent myostatin in a pH dependent manner
  9. Drug

    PF-03882845

    go.drugbank.com/drugs/DB11814
    Investigational

    PF-03882845 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 and Type 2 Diabetic Nephropathy.

  10. Drug

    Tomivosertib

    go.drugbank.com/drugs/DB15219
    Investigational

    Tomivosertib is under investigation in clinical trial NCT03318562 (A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC).